Design Therapeutics (DSGN) Assets (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Assets of $215.1 million for Q2 2026, down 3.48% year-over-year from $222.9 million in Q2 2025, and down 6.65% on a QoQ basis from $230.4 million in Q1 2026.
Design Therapeutics (DSGN) Assets (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Assets for 7 years, with the latest figure at $215.1 million in Q2 2026.
- Assets for Q2 2026 came in at $215.1 million, down 3.48% year-over-year; the trailing twelve-month figure through Jun 2026 was $215.1 million (down 3.48% YoY), and the FY2025 annual result was $226.2 million, down 10.27% from the prior year.
- Assets fell to $215.1 million in Q2 2026, from $230.4 million in the prior quarter.
- Over five years, Assets peaked at $378.8 million in Q1 2022 and troughed at $211.8 million in Q3 2025.
- A 5-year average of $281.9 million and a median of $274.2 million in 2024 frame the typical range for Assets.
- The widest annual swing landed in 2025, when Assets declined 19.06%; it then dropped 2.96% in 2026.
- A 5-year view of Assets shows it stood at $341.1 million in 2022, then declined by 15.09% to $289.6 million in 2023, then declined by 12.96% to $252.1 million in 2024, then dropped by 10.27% to $226.2 million in 2025, then fell by 4.9% to $215.1 million in 2026.
- Per Business Quant data, the three most recent Assets figures were $215.1 million in Q2 2026, $230.4 million in Q1 2026, and $226.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 215.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215.13 Mn |
| Mar 31, 2026 | 230.44 Mn |
| Dec 31, 2025 | 226.20 Mn |
| Sep 30, 2025 | 211.77 Mn |
| Jun 30, 2025 | 222.89 Mn |
| Mar 31, 2025 | 237.48 Mn |
| Dec 31, 2024 | 252.09 Mn |
| Sep 30, 2024 | 261.63 Mn |
| Jun 30, 2024 | 269.58 Mn |
| Mar 31, 2024 | 278.79 Mn |
| Dec 31, 2023 | 289.64 Mn |
| Sep 30, 2023 | 299.87 Mn |
| Jun 30, 2023 | 311.63 Mn |
| Mar 31, 2023 | 324.74 Mn |
| Dec 31, 2022 | 341.14 Mn |
| Sep 30, 2022 | 354.57 Mn |
| Jun 30, 2022 | 367.93 Mn |
| Mar 31, 2022 | 378.80 Mn |
| Dec 31, 2021 | 390.56 Mn |
| Sep 30, 2021 | 400.35 Mn |